Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

Is Rocket Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals or view top-rated stocks.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Rocket Pharmaceuticals.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.04. During the same period in the previous year, the company posted ($0.65) earnings per share.
View Rocket Pharmaceuticals' earnings history.

What price target have analysts set for RCKT?

5 equities research analysts have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their forecasts range from $62.00 to $67.00. On average, they anticipate Rocket Pharmaceuticals' stock price to reach $64.25 in the next twelve months. This suggests a possible upside of 455.8% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:

• Dr. Gaurav D. Shah, CEO & Director (Age 47, Pay $1.04M)
• Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, Pres, COO & Head of Devel. (Age 43, Pay $825.9k)
• Mr. John C. Militello CPA, CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer (Age 49, Pay $385.78k)
• Mr. Jonathan Schwartz, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 58, Pay $619.7k)
• Mayur Kasetty M.B.A., M.D., Bus. Devel. & Operations and Investor Relations Lead
• Ms. Jessie Yeung M.B.A., VP of Investor Relations & Corp. Fin.
• Mr. Martin L. Wilson, Gen. Counsel, Chief Compliance Officer & Sr. VP (Age 45)
• Kevin Giordano, Director of Corp. Communications
• Ms. Isabel Carmona J.D., Sr. VP & Chief HR Officer
• Dr. Gayatri R. Rao J.D., M.D., Chief Devel. Officer of LVV & Sr. VP

Who are some of Rocket Pharmaceuticals' key competitors?

Some companies that are related to Rocket Pharmaceuticals include Pacira BioSciences (PCRX), Zai Lab (ZLAB), Indivior (INVVY), Prestige Consumer Healthcare (PBH), ACADIA Pharmaceuticals (ACAD), Harmony Biosciences (HRMY), EQRx (EQRX), Insmed (INSM), Arvinas (ARVN), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), OPKO Health (OPK), PTC Therapeutics (PTCT) and Sage Therapeutics (SAGE).
View all of RCKT's competitors.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (5.27%), Vanguard Group Inc. (5.09%), BlackRock Inc. (5.16%), State Street Corp (4.18%), Maverick Capital Ltd. (3.24%) and Goldman Sachs Group Inc. (2.36%). Company insiders that own Rocket Pharmaceuticals stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals.

Which institutional investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Ghost Tree Capital LLC, Citigroup Inc., Sectoral Asset Management Inc., Mirae Asset Global Investments Co. Ltd., Wellington Management Group LLP, Harbor Capital Advisors Inc., and Allianz Asset Management GmbH. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include Gotham Makker, and Jonathan David Schwartz.
View insider buying and selling activity for Rocket Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Federated Hermes Inc., State Street Corp, Healthcare of Ontario Pension Plan Trust Fund, Maverick Capital Ltd., M28 Capital Management LP, and JPMorgan Chase & Co.. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Gaurav Shah, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $11.56.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals has a market capitalization of $761.09 million. The biotechnology company earns $-169.07 million in net income (profit) each year or ($2.700010) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals employs 151 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at (646) 440-9100, via email at [email protected], or via fax at 646-224-9585.